Singular Immune has developed an innovative recombinant protein-based platform for in vivo cell engineering. This platform enables the modification of various cells to create therapeutic interventions for cancer, autoimmune diseases, inflammatory diseases, and heart diseases.
Utilizing this platform, we have successfully demonstrated the feasibility of generating Chimeric Antigen Receptor-Natural Killer (CAR-NK) cells in vivo through systemic infusion of the in vivo CAR (iCAR) protein. The iCAR technology offers an immediate and cell-free CAR therapy option for patients with hematologic or solid organ malignancies, eliminating the need for costly and time-consuming ex vivo expansion of CAR-immune cells.
David A. Bull, M.D., is Co-Founder and Chief Executive Officer at Singular Immune. He is a cardiothoracic surgeon with research experience in clinical/translational gene and protein therapies for over 30 years.
Youngwook Won, Ph.D.
Co-Founder and Chief Scientific Officer
Youngwook Won, Ph.D., is Co-Founder and Chief Scientific Officer at Singular Immune, as well as an Associate Professor at the University of North Texas. Dr. Won has over 17 years of experience in the field of cell and protein engineering.
Seungmin Han, Ph.D.
Principal Scientist / Co-Inventor
Seungmin Han, Ph.D., is a principal scientist at Singular Immune. For the past decade, her research has focused on gene and protein delivery for immunotherapy and stem cell therapy.
